AnaptysBio Inc (ANAB.OQ)
ANAB.OQ on NASDAQ Stock Exchange Global Select Market
82.62USD
15 Aug 2018
82.62USD
15 Aug 2018
Change (% chg)
$-0.42 (-0.51%)
$-0.42 (-0.51%)
Prev Close
$83.04
$83.04
Open
$80.76
$80.76
Day's High
$83.66
$83.66
Day's Low
$80.28
$80.28
Volume
153,641
153,641
Avg. Vol
129,440
129,440
52-wk High
$134.00
$134.00
52-wk Low
$20.12
$20.12
About
AnaptysBio, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro,... (more)
Overall
| Beta: | -- |
| Market Cap(Mil.): | $725.82 |
| Shares Outstanding(Mil.): | 20.34 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| ANAB.OQ | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 85.68 | 32.76 |
| EPS (TTM): | -1.06 | -- | -- |
| ROI: | -23.31 | 1.78 | 14.61 |
| ROE: | -48.33 | 3.28 | 16.33 |
BRIEF-Anaptysbio Qtrly Loss Per Share $0.63
* ANAPTYSBIO ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES PIPELINE UPDATES
BRIEF-Anaptysbio Announces Positive Top-Line Proof-Of-Concept Data For ANB020 In Moderate-To-Severe Baseline Adult Peanut Allergy Patients
* ANAPTYSBIO ANNOUNCES POSITIVE TOP-LINE PROOF-OF-CONCEPT DATA FOR ANB020 IN MODERATE-TO-SEVERE BASELINE ADULT PEANUT ALLERGY PATIENTS
BRIEF-AnaptysBio Qtrly Loss Per Share $0.30
* ANAPTYSBIO ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND 2018 PIPELINE MILESTONES
Competitors
| Price | Chg | |
|---|---|---|
| Roche Holding Ltd. (ROG.S) | CHF237.25 | -- |
| Roche Holding Ltd. (RO.S) | CHF240.60 | -- |
| GlaxoSmithKline plc (GSK.L) | 1,590.40 | -- |
| Teva Pharmaceutical Industries Limited (TEVA.TA) | 8,066.00 | -- |
| Allergy Therapeutics plc (AGY.L) | 26.25 | -- |
| AstraZeneca plc (AZN.L) | 5,942.00 | -- |
| Pfizer Inc. (PFE.N) | $41.16 | +0.45 |
| Regeneron Pharmaceuticals Inc (REGN.OQ) | $361.87 | -4.36 |
| Sanofi SA (SASY.PA) | €72.16 | -- |
| Amgen, Inc. (AMGN.OQ) | $195.26 | -0.50 |
Estimates